Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
| IMRX Stock | USD 2.15 0.04 1.90% |
Slightly above 55% of Immuneering Corp's investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Immuneering Corp suggests that some traders are interested. Immuneering Corp's investing sentiment can be driven by a variety of factors including economic data, Immuneering Corp's earnings reports, geopolitical events, and overall market trends.
Immuneering |
- The company will provide additional data from IMM-1-104 in combination with modified gemcitabinenab-paclitaxel in first-line pancreatic cancer - - The company will also provide initial data from IMM-1-104 in combination with modified FOLFIRINOX in first-line pancreatic cancer, as well as IMM-1-104 monotherapy in second-line pancreatic cancer - CAMBRIDGE, Mass., Dec. 17, 2024 -- Immuneering Corporation , a clinical-stage oncology company seeking to
Read at finance.yahoo.com
 |
Immuneering Corp Fundamental Analysis
We analyze Immuneering Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immuneering Corp using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immuneering Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Employees
Number Of Employees Comparative Analysis
Immuneering Corp is currently under evaluation in number of employees category among its peers. Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Immuneering Corp Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Immuneering Corp stock to make a market-neutral strategy. Peer analysis of Immuneering Corp could also be used in its relative valuation, which is a method of valuing Immuneering Corp by comparing valuation metrics with similar companies.
Peers
Immuneering Corp Related Equities
| CMPX | Compass Therapeutics | 20.16 | ||||
| IVA | Inventiva | 16.13 | ||||
| REPL | Replimune | 5.61 | ||||
| PMVP | Pmv Pharmaceuticals | 5.30 | ||||
| NVCT | Nuvectis Pharma | 5.25 | ||||
| LRMR | Larimar Therapeutics | 4.91 | ||||
| CELC | Celcuity LLC | 3.46 | ||||
| KRON | Kronos Bio | 1.01 | ||||
| CGEM | Cullinan Oncology | 0.48 | ||||
| ELVN | Enliven Therapeutics | 0.23 | ||||
| GLUE | Monte Rosa | 0.54 | ||||
| IKNA | Ikena Oncology | 0.68 | ||||
| NAMS | NewAmsterdam Pharma | 1.39 | ||||
| GOSS | Gossamer Bio | 2.17 | ||||
| CNTA | Centessa Pharmaceuticals | 2.40 | ||||
| LYRA | Lyra Therapeutics | 5.00 |
Additional Tools for Immuneering Stock Analysis
When running Immuneering Corp's price analysis, check to measure Immuneering Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immuneering Corp is operating at the current time. Most of Immuneering Corp's value examination focuses on studying past and present price action to predict the probability of Immuneering Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immuneering Corp's price. Additionally, you may evaluate how the addition of Immuneering Corp to your portfolios can decrease your overall portfolio volatility.